ABSTRACT
Objective To evaluate the immunity efficacy of human amniotic membranes on rats. Methods One hundred and fifty Wistar rats were randomly divided into five groups:biological amnion group,immunosuppression group,immunostimulation group, sham-operated group and blank control group. According to the study period,each group of thirty rats would be randomly divided into five experimental operation subgroups:the 1st week,the 2nd week,the 4th week,the 8th week group and the 12th week groups. The rats were implanted subcutaneously,then intramuscular injection of gentamicin sulfate for 3 days to resist the infection ,and the immune organ coefficient,and the killing abilities of NK cell ,IL-1β,IL-6 and TNF-αserum levels were detected according to the study period.Results At 1st ,2nd ,4th ,8th and 12th week after amniotic membrane implantation in rats,compared with the sham-operated and blank control groups,the biological amnion group had nonsignificant differences (P>0.05). At 1st week after amniotic membrane implantation in rats, immunosuppression group showed different levels of the immunosuppressive effect,such as the analysis of immune organ coefficient , which had significant differences compared with other groups (P<0.01). At 1st week after amniotic membrane implantation in rats,the imunostimulation group showed a certain degree of the immunostimulant effect,such as the killing abilities of NK cell,which had marked differences compared with other groups (P<0.05). Conclusion The amniotic membranes have satisfactory immune safety with implantation in rats and do not cause significant adverse immune reactions.
ABSTRACT
In both clinical and animal experiments,it has been confirmed that the inflammation in brain is involved in the development of brain damage after the ischemia.However,the pro-inflammatory mechanism is extremely complicated.Recently,a growing number of reports indicates that many factors play their roles in the inflammation,such as leukocyte,interleukin-1?(IL-1?),tumor necrosis factor(TNF)and mast cells.They are released/presented in the region of cerebral ischemia and include both ischemic and secondary brain injury.
